227 related articles for article (PubMed ID: 12114433)
1. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.
Toyooka S; Fukuyama Y; Wistuba II; Tockman MS; Minna JD; Gazdar AF
Clin Cancer Res; 2002 Jul; 8(7):2292-7. PubMed ID: 12114433
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas.
Ono K; Uzawa K; Nakatsuru M; Shiiba M; Mochida Y; Tada A; Bukawa H; Miyakawa A; Yokoe H; Tanzawa H
Int J Oncol; 2003 Aug; 23(2):297-302. PubMed ID: 12851677
[TBL] [Abstract][Full Text] [Related]
3. Fez1/lzts1 alterations in gastric carcinoma.
Vecchione A; Ishii H; Shiao YH; Trapasso F; Rugge M; Tamburrino JF; Murakumo Y; Alder H; Croce CM; Baffa R
Clin Cancer Res; 2001 Jun; 7(6):1546-52. PubMed ID: 11410489
[TBL] [Abstract][Full Text] [Related]
4. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.
Nonaka D; Fabbri A; Roz L; Mariani L; Vecchione A; Moore GW; Tavecchio L; Croce CM; Sozzi G
Cancer Res; 2005 Feb; 65(4):1207-12. PubMed ID: 15735004
[TBL] [Abstract][Full Text] [Related]
5. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
[TBL] [Abstract][Full Text] [Related]
7. Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.
Heller G; Fong KM; Girard L; Seidl S; End-Pfützenreuter A; Lang G; Gazdar AF; Minna JD; Zielinski CC; Zöchbauer-Müller S
Oncogene; 2006 Feb; 25(6):959-68. PubMed ID: 16205641
[TBL] [Abstract][Full Text] [Related]
8. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis.
Uzawa K; Ono K; Suzuki H; Tanaka C; Yakushiji T; Yamamoto N; Yokoe H; Tanzawa H
Clin Cancer Res; 2002 Mar; 8(3):828-35. PubMed ID: 11895916
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic down-regulation of death-associated protein kinase in lung cancers.
Toyooka S; Toyooka KO; Miyajima K; Reddy JL; Toyota M; Sathyanarayana UG; Padar A; Tockman MS; Lam S; Shivapurkar N; Gazdar AF
Clin Cancer Res; 2003 Aug; 9(8):3034-41. PubMed ID: 12912953
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
13. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of laminin-5-encoding genes in lung cancers.
Sathyanarayana UG; Toyooka S; Padar A; Takahashi T; Brambilla E; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Jul; 9(7):2665-72. PubMed ID: 12855645
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
Kim TY; Jong HS; Song SH; Dimtchev A; Jeong SJ; Lee JW; Kim TY; Kim NK; Jung M; Bang YJ
Oncogene; 2003 Jun; 22(25):3943-51. PubMed ID: 12813468
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer.
Knowles MA; Aveyard JS; Taylor CF; Harnden P; Bass S
Cancer Lett; 2005 Jul; 225(1):121-30. PubMed ID: 15922864
[TBL] [Abstract][Full Text] [Related]
17. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
18. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
[TBL] [Abstract][Full Text] [Related]
19. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
Cohen AJ; Bunn PA; Franklin W; Magill-Solc C; Hartmann C; Helfrich B; Gilman L; Folkvord J; Helm K; Miller YE
Cancer Res; 1996 Feb; 56(4):831-9. PubMed ID: 8631021
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
Kikuchi S; Yamada D; Fukami T; Masuda M; Sakurai-Yageta M; Williams YN; Maruyama T; Asamura H; Matsuno Y; Onizuka M; Murakami Y
Clin Cancer Res; 2005 Apr; 11(8):2954-61. PubMed ID: 15837747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
